- Home
- NVVE vs ADVB Comparison
NVVE vs ADVB Comparison
Compare NVVE & ADVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NVVE | ADVB |
|---|---|---|
| Founded | 1996 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil Refining/Marketing | Medical Specialities |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.2M | 8.4M |
| IPO Year | N/A | 2025 |
Fundamental Metrics
Financial Performance| Metric | NVVE | ADVB |
|---|---|---|
| Price | $3.46 | $0.35 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 240.8K | ★ 1.2M |
| Earning Date | 11-13-2025 | 02-03-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $4,630,156.00 | N/A |
| Revenue This Year | $892.33 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.98 | $0.28 |
| 52 Week High | $200.80 | $4.10 |
Technical Indicators
Market Signals| Indicator | NVVE | ADVB |
|---|---|---|
| Relative Strength Index (RSI) | 67.51 | 44.20 |
| Support Level | $1.98 | $0.28 |
| Resistance Level | $4.14 | $0.36 |
| Average True Range (ATR) | 0.52 | 0.04 |
| MACD | -0.10 | 0.00 |
| Stochastic Oscillator | 63.22 | 51.12 |
Price Performance
Historical ComparisonAbout NVVE Nuvve Holding Corp.
Nuvve Holding Corp is accelerating the electrification of transportation through its proprietary vehicle-to-grid (V2G) technology. It helps to support the integration of renewable energy sources, including solar and wind. Its Grid Integrated Vehicle (GIV) platform is refueling the next generation of electric vehicle fleets through bidirectional charging solutions. It has a geographic presence in the United States, the United Kingdom, and Denmark, of which it generates the majority of its revenue in the United States.
About ADVB Advanced Biomed Inc.
Advanced Biomed Inc operates through its subsidiaries and is mainly engaged in the research and development of various original microfluidic biochip technologies and the provision of tumor precision diagnosis and treatment technology applications. Through the joint application of semiconductor technology and biotechnology, it has developed various technologies and testing equipment for early screening and detection, diagnosis and staging, and treatment of cancer. Its devices: A+Pre, AC-1000, A+CellScan, and A+SCDrop, and three corresponding microfluidic biochips, A+Pre Chip and AC-1000 CTC Enrichment Chip, and A+CellScan Chip, are designed to provide rapid and affordable assay products and services to cancer patients.